Advertisement
Abstract

Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.

J W Aiken, R J Shebuski, O V Miller and R R Gorman
Journal of Pharmacology and Experimental Therapeutics November 1981, 219 (2) 299-308;

Article Information

vol. 219 no. 2 299-308
PubMed 
6270303
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103

Statistics from Altmetric.com

Article usage

Article usage: August 2006 to January 2024

AbstractFullPdf
Aug 2006001
Sep 2006004
Jan 2007001
Nov 2007001
Jun 2008002
Jul 2008001
Mar 2009001
Jul 2009003
Oct 2009001
Dec 2009004
Apr 2010002
Aug 2010002
Oct 2010002
Mar 2011004
Sep 2011001
Dec 2011001
Jan 2012001
Apr 2012002
May 2012001
Nov 2012001
Dec 2012003
Apr 2013001
Jun 2013003
Jul 2013100
Dec 2013001
Jan 2014001
Apr 2014001
May 2014100
Jul 2014002
Jan 2015001
Feb 2015001
Apr 2015100
Dec 2015001
Feb 2016001
Apr 2016002
Aug 2016001
Sep 2016002
Feb 2017001
Jul 2017003
Sep 2017003
Oct 2017001
Nov 2017002
Dec 2017001
Mar 2018001
Apr 2018001
May 2018002
Jun 2018001
Jul 2018003
Dec 2018001
Jul 2019002
Oct 2020001
Jan 2024001

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Abstract

Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.

J W Aiken, R J Shebuski, O V Miller and R R Gorman
Journal of Pharmacology and Experimental Therapeutics November 1, 1981, 219 (2) 299-308;
Twitter logo Facebook logo Mendeley logo

Jump to section

Related Articles

Cited By...

Similar Articles

Advertisement